Press releases

May 25, 2018
Wilson Therapeutics applies for delisting
Read more

May 16, 2018
Wilson Therapeutics AB (Publ) Interim report January 1 – March 31, 2018
Read more

May 16, 2018
Notice of annual general meeting in Wilson Therapeutics
Read more

Apr 27, 2018
Wilson Therapeutics’ 2017 Annual Report published
Read more

Apr 12, 2018
Promising preliminary long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting
Read more

Apr 11, 2018
Statement by the Independent Committee of the Board of Directors of Wilson Therapeutics in relation to the public offer from Alexion
Read more

Mar 28, 2018
Preliminary long-term data for WTX101 in Wilson Disease accepted as a late-breaker presentation at EASL Annual Meeting
Read more

Mar 21, 2018
Wilson Therapeutics hosts Capital Markets Day today at 13:30 CET/08:30 EDT
Read more

Mar 12, 2018
Wilson Therapeutics announces agenda for Capital Markets Day on 21 March 2018
Read more

Mar 06, 2018
Wilson Therapeutics to Present at Upcoming Investor Conferences
Read more

Feb 21, 2018
Wilson Therapeutics AB (Publ) Year-End Report 2017
Read more

Feb 19, 2018
SAVE THE DATE: Wilson Therapeutics to Host Capital Markets Day in Stockholm on 21 March 2018
Read more

Feb 16, 2018
First patient enrolled in pivotal Phase 3 FOCuS trial evaluating WTX101 for the treatment of Wilson Disease
Read more

Feb 14, 2018
Wilson Therapeutics to host conference call to provide fourth quarter 2017 business update
Read more